This week in therapeutics




Licensing status

Publication and contact information

Infectious disease


Plasmodium falciparum multidrug resistance protein 1 (PfMDR1)

In vitro and cell culture studies identified a PfMDR1-targeting compound, ACT-213615, that could help treat malaria. In biochemical studies with P. falciparum cell lysates, ACT-213615 bound directly to PfMDR1. In P. falciparum cultures, ACT-213615 decreased proliferation at all asexual stages of the parasite cell cycle compared with an inactive control compound. Next steps could include optimizing the lead compound and testing it in models for malarial infection.
Actelion Ltd. has an undisclosed molecule in Phase I testing for malaria.

SciBX 6(29); doi:10.1038/scibx.2013.763
Published online Aug. 1, 2013

Patented by Actelion; available for licensing

Brunner, R. et al. J. Biol. Chem.; published online June 10, 2013;
Contact: Christoph Binkert, Actelion Ltd., Allschwil, Switzerland